secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001437749-24-002083
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela faces Nasdaq delisting over public float shortfall; ASPIRE trial enrollment >50%
--------------------------------------------------------------------------------

- Nasdaq staff notified Panbela that after 1-for-20 reverse split on Jan 18, publicly held shares fell below 500,000 minimum.
- Delisting hearing scheduled for bid price and equity compliance; this additional non-compliance basis will be considered by panel.
- Common stock remains listed on Nasdaq Capital Market pending hearing outcome; no assurance of continued listing.
- ASPIRE global phase 3 trial for ivospemin in metastatic pancreatic cancer exceeded 50% enrollment; interim data expected mid-2024.
- Full enrollment projected by Q1 2025; trial has about 90 sites across US, Europe, Australia, and South Korea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/0001437749-24-002083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/pbla20240124_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-002083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer